FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one product on the market for cartilage repair, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with one marketed product and a strong clinical stage pipeline of adult stem cell programs.
The company’s commercial product, ChondroCelect®, for cartilage repair in the knee, is the first and only approved cell-based product in Europe, and is currently being launched in different European countries.
TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived mesenchymal stem cells (eASCs) and targeting autoimmune and inflammatory diseases. They are built on solid pre-clinical and CMC packages, and are being developed in close consultation with the European Medicines Agency. The company is conducting a Phase III clinical trial in complex perianal fistulas in patients with Crohn’s disease, a Phase IIa trial in rheumatoid arthritis, and in early 2012 successfully concluded a Phase I trial to investigate the potential of intra-lymphatic administration of eASCs for autoimmune disorders.
TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
ChondroCelect, the company’s product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, through clinical development to central European registration as a medicinal product. ChondroCelect consists of characterized cultured chondrocytes derived from the patient’s own cartilage and is used for autologous chondrocyte implantation (ACI), a surgical procedure to treat cartilage defects. ChondroCelect received European marketing authorisation as the first Advanced Therapy Medicinal Product, indicated for repair of single symptomatic cartilage defects of the femoral condyle of the knee in adults.
Phone: +32 16 39 60 60
Fax: +32 16 39 60 70
Foundation date: 1/2000